SHANGHAI–()–ITabMed Ltd., a clinical-stage biotech company in China, announced the IND approval from China National Medical Products Administration (NMPA) for A-337, a CD3-activating bi-specific antibody targeting EpCAM. This is a “Phase I…
Originalartikel lesen: …treat solid tumors – Business Wire China
